Thomas Christely takes ceo role at Silence Therapeutics

Based at RNAi firm’s facility in Berlin, Germany

Silence Therapeutics, a global RNA interference (RNAi) therapeutics company headquartered in London, UK, has promoted Thomas Christely to the position of chief executive. He is based at Silence's facility in Berlin, Germany.

Christely brings more than 20 years’ experience in corporate and business development and finance to the firm. He was instrumental in the merger of Silence Therapeutics (formerly Atugen) with Silence Therapeutics (formerly SR Pharma) and admission to the Alternative Investment Market of the London Stock Exchange.

Christely joined Atugen in 2001 as chief financial officer and became chief operating officer in 2002 before being appointed its chief executive in 2006.

Prior to joining Silence, he was senior vp and cfo at OXO Chemie, a Swiss pharmaceutical company, and founded its subsidiary OXO Chemie Inc in San Francisco, where he stayed from 1997 until 2000.

You may also like

Ingredients

AstraZeneca joins forces with Silence to develop siRNA therapeutics

Collaboration with Silence Therapeutics has been agreed to develop small interfering RNA therapeutics that act inside the cell to influence protein production
Regulatory

Silence strengthens US patent estate

Silence Therapeutics, developers of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announced a further key US patent 9,695,423 has been granted to Silence this month
Research & Development

Silence Therapeutics to collaborate with Mirna

To evaluate delivery of new microRNA therapeutics
Research & Development

Silence Therapeutics and AstraZeneca extend siRNA deal

12-month extension to collaboration for the development of five siRNA programmes
Research & Development

A silent revolution

Increased understanding of RNA interference has led to an explosion of gene silencing drug research projects. Dr Sarah Houlton reviews the progress being made in recent drug trials and looks at the remaining challenges
Research & Development

Silence Therapeutics and Dainippon Sumitomo expand siRNA collaboration

Companies to examine delivery of RNAi therapeutics to additional disease targets
Research & Development

Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells

Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Subscribe now